妥布霉素
阿奇霉素
医学
安慰剂
囊性纤维化
痰
铜绿假单胞菌
内科学
抗生素
麻醉
病理
微生物学
肺结核
细菌
替代医学
生物
遗传学
作者
David P. Nichols,Pradeep Kumar Singh,Arthur Baines,Lindsay J. Caverly,James F. Chmiel,Ronald L. Gibson,Jorge E. Lascano,Sarah J. Morgan,George Z. Retsch‐Bogart,Lisa M. Saiman,Hossein Sadeghi,Joanne L. Billings,Sonya L. Heltshe,Shannon Kirby,Ada Kong,Jerry A. Nick,Nicole Mayer-Hamblett
出处
期刊:Thorax
[BMJ]
日期:2021-10-27
卷期号:77 (6): 581-588
被引量:29
标识
DOI:10.1136/thoraxjnl-2021-217782
摘要
Rationale Inhaled tobramycin and oral azithromycin are common chronic therapies in people with cystic fibrosis andPseudomonas aeruginosaairway infection. Some studies have shown that azithromycin can reduce the ability of tobramycin to killP. aeruginosa. This trial was done to test the effects of combining azithromycin with inhaled tobramycin on clinical and microbiological outcomes in people already using inhaled tobramycin. We theorised that those randomised to placebo (no azithromycin) would have greater improvement in forced expiratory volume in one second (FEV1) and greater reduction inP. aeruginosasputum in response to tobramycin. Methods A 6-week prospective, randomised, placebo-controlled, double-blind trial testing oral azithromycin versus placebo combined with clinically prescribed inhaled tobramycin in individuals with cystic fibrosis andP. aeruginosaairway infection. Results Over a 6-week period, including 4 weeks of inhaled tobramycin, the relative change in FEV1did not statistically significantly differ between groups (azithromycin (n=56) minus placebo (n=52) difference: 3.44%; 95% CI: −0.48 to 7.35; p=0.085). Differences in secondary clinical outcomes, including patient-reported symptom scores, weight and need for additional antibiotics, did not significantly differ. Among the 29 azithromycin and 35 placebo participants providing paired sputum samples, the 6-week change inP. aeruginosadensity differed in favour of the placebo group (difference: 0.75 log10CFU/mL; 95% CI: 0.03 to 1.47; p=0.043). Conclusions Despite having greater reduction inP. aeruginosadensity in participants able to provide sputum samples, participants randomised to placebo with inhaled tobramycin did not experience significantly greater improvements in lung function or other clinical outcomes compared with those randomised to azithromycin with tobramycin.
科研通智能强力驱动
Strongly Powered by AbleSci AI